Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis

Table 1 Baseline characteristics of included studies

Ref.	Study design	Sample size (n)	Age	Subtypes (3A/3B), (%)	Co-infection with HIV (%)	Baseline NS5A RAS (%)	Prior treatment (%)	SVR12 ITT (%)	SVR12 PP (%)	Treatment-related adverse event (%)
Pianko et al[22], 2015	RCT	52	I: 54.0 (44-65); C: 56 (45-68)	NR	0	NR	I: 100.0; C: 100.0	I: 96.2; C: 88.5	I: 96.2; C: 88.5	NR
Esteban et al[16], 2018	RCT	204	I: 51 ± 7.6; C: 51 ± 7.3	I: 100.0/0.0; C: 99.0/1.0	I: 15.5; C: 13.9	I: 21.8; C: 19.4	I: 27.2; C: 26.7	I: 96.1; C: 91.1	I: 96.1; C: 92.0	I: 4.9; C: 1.0
von Felden et al[23], 2018	Cohort study	65	NR	NR	I: 2.9; C: 13.3	I: 11.4; C: 0.0	I: 37.1; C: 23.3	I: 100.0; C: 96.7	NR	NR
Drysdale et al[26], 2019	Cohort study	414	NR	NR	NR	NR	NR	NR	I: 98.0; C: 91.7	NR
Pasulo et al[27], 2019	Cohort study	130	NR	NR	NR	NR	NR	NR	I: 93.9; C: 98.4	NR
Hlaing et al[24], 2019	Cohort study	60	NR	NR	NR	NR	NR	NR	I: 100.0; C: 96.0	I: 31.4; C: 8.0
Wong et al[30], 2020	Cohort study	163	NR	NR	NR	NR	NR	I: 97.8; C: 97.5	I: 97.8; C: 97.5	NR

HIV: Human immunodeficiency virus; NS5A: Non-structural protein 5A; RAS: Resistance-associated substitution; SVR12: Sustained virological response 12 wk post treatment; ITT: Intention-to-treat; PP: Per-protocol; RCT: Randomized controlled trial; I: Intervention (sofosbuvir/velpatasvir + ribavirin), C: Control (sofosbuvir/velpatasvir), NR: Not reported.